Z Gastroenterol 2015; 53(1): 54-58
© Georg Thieme Verlag KG Stuttgart · New York
Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Vedolizumab-Nutzenbewertung gemäß § 35a SGB V des G-BA
Literaturverzeichnis
1 Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. Journal of Crohn‘s & colitis 2012; 6: 991-1030
2 Dignass A, Preiss JC, Aust DE et al. [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. Z Gastroenterol 2011; 49: 1276-1341
3 Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn‘s disease: Current management. Journal of Crohn‘s & colitis 2010; 4: 28-62
4 Preiß JC, Bokemeyer B, Buhr H-J et al. Aktualisierte S3 Leitlinie „Diagnostik und Therapie des Morbus Crohn“ 2014. Z Gastroenterol 2014; in press
5 Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn‘s disease: a review. The American journal of gastroenterology 2009; 104: 760-767
6 Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn‘s disease. Alimentary pharmacology & therapeutics 2011; 33: 987-995
7 Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn‘s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
8 Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn‘s disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
9 Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn‘s disease. The New England journal of medicine 2007; 357: 239-250
10 D‘Haens GR, Panaccione R, Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn‘s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. The American journal of gastroenterology 2011; 106: 199-212 ; quiz 3
11 Ramadas AV, Gunesh S, Thomas GA et al. Natural history of Crohn‘s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-1206
12 Bernstein CN, Loftus Jr EV, Ng SC et al.. Hospitalisations and surgery in Crohn‘s disease. Gut 2012; 61: 622-629
13 Van Assche G, Dignass A, Bokemeyer B et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. Journal of Crohn‘s & colitis 2013; 7: 1-33
14 Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265 e1-3
15 Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine 2013; 369: 699-710
16 Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scandinavian journal of gastroenterology 2009; 44: 431-40
17 Froslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422
18 Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
19 Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England journal of medicine 2005; 353: 2462-2476
20 Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011; 9: 483-489 e3
21 Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459
22 Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787
23 Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn‘s disease. The New England journal of medicine 2013; 369: 711-721
24 Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn‘s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-627 e3
25 D‘Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786
26 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. The New England journal of medicine 1987; 317: 1625-1629
